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Abstract
Toll-like receptor 9 (TLR9) is highly expressed in B cells and B cells are important in the 
pathogenesis of type 1 diabetes (T1D) development.  However, the intrinsic effect of TLR9 in B 
cells on beta cell autoimmunity is not known.  To fill this knowledge gap, we generated non-
obese diabetic (NOD) mice with a B cell-specific deficiency of TLR9 (TLR9fl/fl/CD19-Cre+ 
NOD).  The B cell-specific deletion of TLR9 resulted in near complete protection from T1D 
development.  Diabetes protection was accompanied by an increased proportion of IL-10-
producing B cells.  We also found that TLR9-deficient B cells were hyporesponsive to both 
innate and adaptive immune-stimuli.  This suggested that TLR9 in B cells modulates T1D 
susceptibility in NOD mice by changing the frequency and function of IL-10-producing B cells.  
Molecular analysis revealed a network of TLR9 with MMPs, TIMP1 and CD40, all of which are 
inter-connected with IL-10.  Our study has highlighted an important connection of an innate 
immune molecule in B cells to the immuno-pathogenesis of T1D.  Thus, targeting the TLR9 
pathway, specifically in B cells, may provide a novel therapeutic strategy for T1D treatment.
Page 2 of 44Diabetes
3
Introduction
Toll-like receptors (TLRs) are innate immune receptors that recognize molecular patterns of 
microbial pathogens.  On binding to the appropriate ligands, TLRs activate signaling pathways 
that lead to production of proinflammatory cytokines [1, 2] and upregulation of co-stimulatory 
molecules [3, 4].  TLR9 has been shown to be expressed on a range of immune cells including B 
cells [5, 6], dendritic cells (DCs) [7, 8], monocytes/macrophages [9, 10], T cells [11], epithelial 
cells [12, 13] and endothelial cells [14].  TLR9 recognizes CG-rich DNA from pathogens and 
self-DNA, as well as short single-stranded synthetic DNA, CpG [15, 16].   TLR9 stimulation 
induces downstream signaling, leading to the induction of a range of cytokines and the 
promotion or suppression of cell survival [17, 18].  TLR9 plays an important role in systemic 
autoimmune diseases, such as systemic lupus erythematosus (SLE), in both humans and a mouse 
model of human SLE [19-21].  In the absence of TLR9, autoimmune disease was exacerbated in 
a mouse model of SLE [22, 23].  Interestingly, a TLR9-deficient Non-Obese Diabetic (NOD) 
mouse model of human type 1 diabetes (T1D) was protected from T1D development [24, 25].  
This protection was partly mediated by impaired IFNα production by dendritic cells (DCs) from 
the TLR9-/- mouse [25] and by enhanced expression and regulatory function of CD73+ T cells, 
as well as by enhanced islet β-cell function [24, 26].  
Expression of TLRs in B cells provides a cell-intrinsic mechanism for innate signals regulating 
adaptive immune responses [22, 27], and studies have suggested that TLR signaling plays vital 
roles in B cell development and activation [6, 28, 29].  Increasing evidence also suggests that B 
cell activation by TLR9 ligands is important for optimal antibody responses to microbial 
antigens and DNAs released from both physiological and pathological dying cells [6, 30].  To 
address the intrinsic role of TLR9 in the function of B cells in a spontaneous autoimmune 
diabetes model system, we generated the non-obese diabetic (NOD) mouse model with a B cell-
specific deficiency of TLR9 (TLR9fl/flCD19-Cre+ NOD).  We hypothesized that TLR9 in B cells 
modulates T1D development by regulating immune tolerance to islet β-cell autoimmunity.  Our 
results showed that B cell-specific TLR9 deficiency led to striking protection from T1D 
development in NOD mice.  Mechanistic studies suggested that TLR9 regulates the IL-10-
producing B cells and that TLR9 deficiency in the B cells changes the proportion and function of 
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IL-10-producing B cells that contribute to diabetes protection.  The molecular mechanism of 
TLR9 regulation of IL-10-producing B cells was mediated by down-regulation of matrix 
metalloproteinases (MMPs) and up-regulation of tissue inhibitors of metalloproteinases (TIMPs) 
gene expression in B cells, leading to protection from diabetes development.
Research Design and Methods
Mice
Mice used in the study were housed in specific pathogen-free conditions with a 12 h dark–light 
cycle at the Yale University animal facility.  TLR9fl/fl C57BL/6 mouse breeders were kindly 
provided by Mark Shlomchik (University of Pittsburgh) and were back-crossed to our NOD/Caj 
genetic background for over 10 generations.  CD19-Cre NOD breeders were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA) and bred with our NOD/Caj mice.  TLR9fl/fl and 
CD19-Cre NOD mice were then inter-crossed to obtain B cell-specific TLR9-deficient (TLR9fl/fl 
CD19-Cre+) and control (TLR9fl/fl/CD19-Cre-) NOD mice.  The total body TLR9- deficient 
(TLR9-/-) NOD mice were generated as previously reported [24, 26]. The use of the animals in 
this study was approved by the Institutional Animal Care and Use Committee of Yale University.
Diabetes incidence monitoring
Diabetes development in TLR9fl/fl/CD19-Cre+ NOD mice and TLR9fl/fl/CD19-Cre- NOD mice 
were monitored weekly for diabetes development by testing for glycosuria with glucose strips 
(Bayer, NJ, USA) from 10 to 32 weeks of age.  Diabetes was diagnosed by two consecutive 
positive glycosuria tests, 24 hours apart and confirmed with a blood glucose reading of 250 
mg/dl (13.9mmol/L), using a FreeStyle glucose meter (Abbott, Chicago, IL, USA).
Monoclonal antibody staining, tetramer staining and flow cytometry
Mononuclear cells were harvested from spleen, pancreatic lymph nodes (PLN), mesenteric 
lymph nodes (MLN), Peyer’s Patches (PP) and peritoneal cavity (PC).  Cells (2-5x106) were first 
incubated with an Fc blocking antibody (CD16/32,15 minutes, 4°C) prior to staining with 
antibodies against CD19, B220, CD40, TCR-beta, CD5, CD1d, CD21, CD23 and a viability dye 
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(all from BioLegend) for 30 minutes at 4°C.  For intracellular cytokine (ICC) staining, the cells 
(5x106) were stimulated with PMA (50ng/ml, Sigma) and Ionomycin (500ng/ml, Sigma) in the 
presence of 1μl/ml GolgiPlugTM (BD) for 4 hours.  Post-stimulation, the cells were stained as 
described above.  After washing, fixation (20 mins at room temperature, RT) and 
permeabilization (eBioscienceTM Intracellular fixation and permeabilization buffer), the cells 
were then incubated with an Fc blocking antibody (15 minutes, 4°C), prior to staining with 
antibodies against cytokines.  PE-conjugated IGRP-tetramer (IGRP206-214, VYLKTNVFL, NIH 
Tetramer Core Facility) staining was carried out with pre-titrated IGRP-tetramer together with 
antibodies against TCR-Vβ8, CD8α, CD44, CD62L, isotype control as well as viability dye.  All 
the samples were analyzed with BD LSRII flow cytometry.
Cell isolation and cell depletion
Splenic B cells were isolated using the EasySepTM Mouse B cell purification kit (STEMCELL 
Technologies), following the manufacturer’s protocol.  Splenic CD4+ T cells were isolated by 
removing CD8+ T cells and antigen presenting cells (APCs).  The splenocytes were incubated 
with hybridoma supernatants containing mAbs to CD8 (TB105) and MHC-II (10.2.16) for 
30mins, at 4°C.  After washing with PBS, the cells were further incubated for 45mins on ice with 
magnetic beads conjugated with goat anti-mouse IgG and IgM (to remove B cells) or goat anti-
rat IgG to remove CD8+ and MHC-II+ cells (all the beads were from QIAGEN).  CD4+ T cells 
were then separated using a magnetic plate.  The purity was routinely 90-95%, as verified by 
flow cytometry.  To deplete splenic Treg cells, we removed CD4+CD25+ T cells by EasySepTM 
Mouse Treg isolation kit (STEMCELL Technologies) and the unbound cells were the Treg-
depleted splenocytes that were used for adoptive transfer.  
Cell culture and transwell co-culture system
Purified B cells (105/well) were stimulated with anti-CD40, with or without anti-IgM or different 
TLR ligands, for 2 days, and the proliferative response was determined by 3H-thymidine 
incorporation.  In a co-culture system, purified B cells, co-cultured with purified T subsets from 
TLR9fl/fl/CD19-Cre- NOD mice, were stimulated with anti-CD3 and anti-CD28.  In a transwell 
co-culture system, purified B cells (105/well) from TLR9fl/fl/CD19-Cre+ NOD mice or 
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TLR9fl/fl/CD19-Cre- NOD mice were added to the insert chambers; purified T cells (105/well) 
from wild type NOD mice, together with T cell-depleted APCs, (105/well), were plated in the 
bottom chamber, in the presence of anti-CD3 and anti-CD28 (final concentration 1μg/ml).  For 
the IL-10 blocking transwell culture, anti-IL-10 receptor mAb (1B1.3A) or control rat IgG was 
added into the culture (insert chamber).  All the cultures were incubated for 2 days in triplicate.  
3H-thymidine was then added and cell culture supernatants were collected.  Cells were incubated 
for a further 18 hours before harvesting.  Proliferation was determined by 3H-Thymidine 
incorporation using a beta-counter and presented as counts per minute (CPM). 
ELISA
Different isotypes of serum immunoglobulins were assessed using direct ELISA (Southern 
Biotech) and the concentrations were determined by standard curve for each isotype (Southern 
Biotech).  IL-10 content of the cell culture supernatants and in serum was determined using the 
Mouse IL-10 ELISA MAXTM Standard kit (BioLegend), based on the manufacturer’s protocol 
provided. 
Adoptive transfer
Purified splenic T cells (5×106) from diabetic NOD mice, together with sorted splenic B cells 
(5×106) from 6-7-week-old TLR9fl/fl/CD19-Cre+ or TLR9fl/fl/CD19-Cre- NOD mice, were 
injected (i.v.) into 5-6-week-old female Rag-/- NOD mice.  Another set of adoptive transfer 
experiments was carried out by transferring Treg-depleted splenocytes (10×106) from 6-7-week-
old TLR9fl/fl/CD19-Cre+ or TLR9fl/fl/CD19-Cre- NOD mice into 5-6-week-old female Rag-/- 
NOD mice.  All the recipients were monitored weekly for glycosuria, and the experiments were 
terminated 12 to 14 weeks after the cell transfer, unless the mice developed diabetes, which was 
confirmed by blood glucose greater than 250 mg/dL (13.9 mmol/l). 
Microarray hybridization and data analysis
Total RNA was extracted from sorted splenic B cells from TLR9fl/fl/CD19-Cre+ or 
TLR9fl/fl/CD19-Cre- NOD mice (7-8-week-old females) with RNeasy Mini kit (Qiagen).  cRNA 
synthesis and whole genome Illumina microarray chip analysis were carried out at the Yale 
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Center for Genomic Analysis. Gene expression data was normalized to control probes and 
performed using Partek Genomics Suite 6.6, and any outliers were removed during quality 
control.
Quantitative real-time PCR (qPCR) 
Splenic B cells from TLR9fl/fl/CD19-Cre+ or TLR9fl/fl/CD19-Cre- NOD mice (7-8-week-old) 
were purified using EasySepTM Mouse B cell and total cellular RNA was isolated with RNeasy 
Mini kit (Qiagen).  cDNA was synthesized using SuperScript III Firststrand synthesis kit with 
random hexamers (Invitrogen).  qPCR was performed with Bio-Rad iQ5 qPCR detection system.  
The relative mRNA levels of IL-10, CD40, TIMP1, MMP19, MMP9 were determined using the 
2-ΔΔCt method, by normalization with the house-keeping gene GAPDH. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism 7 software.  Diabetes incidence was 
compared using log-rank test.  In vitro assays were analyzed with Student's t test or ANOVA and 
P < 0.05 was considered to be statistically significant.
Results
B cell-specific TLR9 deficiency protects against T1D development 
We have previously reported that total body TLR9-deficient NOD mice are protected from T1D 
development [24, 26].  TLR9 is highly expressed in B cells and shown to play an important role 
in systemic autoimmune disorders, such as SLE [31, 32].  To determine the intrinsic role of 
TLR9 in B cells in the immune-pathogenesis of organ-specific autoimmunity, such as T1D, we 
first investigated spontaneous diabetes development in TLR9fl/fl/CD19-Cre- and TLR9fl/fl/CD19-
Cre+ NOD mice.  Interestingly, B cell-specific deletion of TLR9 led to striking protection from 
T1D development (Fig. 1A) and insulitis (Fig.S1). 
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TLR9 intrinsically regulates the frequency and function of B subsets.
To investigate the effect of TLR9 deletion on B cells in a steady state, we evaluated the 
phenotype and function of the B cells from 6-8-week-old female TLR9fl/fl CD19-Cre+ and 
TLR9fl/fl/CD19-Cre- NOD mice ex vivo (Fig.S2, gating strategy).  There was a significant 
increase in CD1d+CD5+ B cells in the PLN and MLN from TLR9fl/fl/CD19-Cre+ NOD mice, 
compared with TLR9fl/fl/CD19-Cre- control mice (Fig. 1B, C).  CD1d+CD5+ B cells are often 
also IL-10-producing B regulatory cells (B10-reg) [33, 34].  Next, we assessed the B10-regs and 
found that B10-regs were increased in all the lymphoid tissues examined from TLR9fl/fl/CD19-
Cre+ NOD mice, compared to TLR9fl/fl/CD19-Cre- controls (Fig.1B, D). However, a statistically 
significant increase in the B10-regs was found only in the PC of TLR9fl/fl/CD19-Cre+ NOD mice 
(Fig.1D).  Interestingly, more IL-10-producing B cells from TLR9fl/fl/CD19-Cre+ NOD mice 
expressed CD40, compared to TLR9fl/fl/CD19-Cre- mice, specifically in the PC (Fig.1E).  The 
absolute cell numbers of different B cell subsets were also changed accordingly (Fig.S3A-E).  
We also evaluated the B10-regs in 30-32-week-old, non-diabetic female mice and found a 
similar phenotype (Fig.1F-H). 
Phenotypic analysis of young mice also revealed a significant increase in marginal zone (MZ) B 
cells (CD21highCD23low) in PLN of TLR9fl/fl/CD19-Cre+ NOD mice, compared to the controls 
(Fig.S4A), whereas transitional B cells (CD21highCD23high) in PLN of TLR9fl/fl/CD19-Cre+ NOD 
mice were significantly reduced (Fig.S4B). Akin to the phenotypic changes in TLR9fl/fl/CD19-
Cre+ NOD mice at a young age, the altered marginal zone and transitional B cells in PLN were 
also seen in the older non-diabetic female mice at 30-32wks (Fig. S4C-D).  Interestingly, unlike 
the young mice, marginal zone B cells (CD21highCD23low) from the spleen and MLN of the older 
mice were decreased in TLR9fl/fl/CD19-Cre+ NOD mice, compared to the control 
TLR9fl/fl/CD19-Cre- NOD mice (Fig.S4C), whereas transitional B cells (CD21highCD23high) from 
PC of old mice were increased in TLR9fl/fl/CD19-Cre+ NOD mice, compared to the controls 
(Fig.S4D).  It is noteworthy that the changes of B cells in PLN remained stable regardless of the 
age of the mice. In addition, relating to IgM and IgD B cell subsets, we showed reduced 
IgM+IgD- B cells and increased IgM+IgD+ B cells in the spleen (Fig.S5A-B).  B cell-specific 
TLR9 deficiency did not affect class switching overall, however, TLR9fl/fl CD19-Cre+ NOD 
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mice showed a significant reduction of IgG, which was attributed to the reduction of IgG1 
(Fig.S6).  Phenotypic analysis of splenic plasmacytes revealed that there was no difference in 
Blimp1+ plasmacytes between TLR9fl/fl/CD19-Cre+ NOD mice and the control mice (Fig.S7A-
B); however, Blimp1- plasmacytes were significantly reduced in TLR9fl/fl/CD19-Cre+ NOD mice 
(Fig.S7C).  Taken together, our data suggest that B cell-specific deletion of TLR9 significantly 
changes proportion of B cell subsets in the various lymphoid organs, which may lead to an 
immune tolerant state and contribute to diabetes protection.
B cells without TLR9 are hypo-responsive to both innate and adaptive immune stimuli
To determine the intrinsic effect of TLR9 on B cell function, we stimulated splenocytes from 
TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice (6-8 wks) with anti-CD40 (adaptive 
stimulus), and innate stimuli including Pam3Csk4, LPS and CpG (TLR2, TLR4 and TLR9 
agonists respectively).  Splenocytes from TLR9 fl/fl/CD19-Cre+ NOD mice showed significantly 
impaired responses to all the stimuli, regardless of whether the cells were stimulated through 
adaptive or innate pathways (Fig. 2A-D).  To verify that the hypo-responsiveness was due to 
TLR9 deficiency in B cells, we repeated the experiments using purified splenic B cells from 
TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice.  We found similarly impaired 
responses to both innate immune and adaptive stimuli, including co-stimulation of anti-CD40 
and anti-IgM (Fig. 2E-I).  To assess if the hypo-response was accompanied by immune-
regulatory cytokines, we measured IL-10 in the supernatants of the anti-CD40 stimulated 
cultures.  Interestingly, we found a significant increase in IL-10 production in the culture 
supernatants, in which B cells from TLR9fl/fl/CD19-Cre+ were used (Fig. 2J).  Moreover, the 
impaired immune response of the TLR9-deficient B cells was also found in the old (30-32 wks) 
TLR9 fl/fl/CD19-Cre+ NOD mice (Fig. 3A-E).  IL-10 in the supernatants of anti-CD40-stimulated 
cultures also were significantly increased in old (30-32 wks) TLR9 fl/fl/CD19-Cre+ NOD mice 
(Fig. 3F).  Taken together, our data suggest that B cell-specific deficiency in TLR9 promotes a B 
cell hypo-responsive immune tolerant state.  
TLR9 regulates the fate of IL-10-producing B cells and suppresses T cell responses.
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To determine if B cell-specific deficiency of TLR9 also led to hypo-responsiveness of T cells, 
we stimulated purified T cells from wild-type NOD mice with anti-CD3 and anti-CD28 
monoclonal antibodies, in the presence of B cells from TLR9fl/fl/CD19-Cre+ or TLR9fl/fl/CD19-
Cre- NOD mice.  Similar to the hypo-responsiveness seen in TLR9-deficient B cells, wild-type 
NOD splenic T cells also showed impaired response to anti-CD3 and anti-CD28 stimulation 
when TLR9-deficient B cells were used for the antibody cross-linking (Fig. 4A).  As TLR9-
deficient B cells secreted a higher level of IL-10 after stimulation (Fig.2J), we hypothesized that 
activated B cells from TLR9fl/fl/CD19-Cre+ NOD mice would have increased regulatory function 
mediated by IL-10.  To test our hypothesis, we performed two sets of experiments using anti-
CD40-activated B cells from TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice, both in 
co-culture and in trans-well culture.  For the former, we cultured purified B cells with and 
without anti-CD40, together with purified T cells from wild-type NOD mice, in the presence of 
anti-CD3 and anti-CD28.  Similar to the results shown in Fig. 4A, the T cell response was 
reduced in the presence of stimulated B cells from TLR9 fl/fl/CD19-Cre+ mice (data not shown).  
To determine if IL-10 played a role in the suppressed T cell response, we measured the secreted 
IL-10 in the culture supernatants.  Similar to the earlier results (Fig.2J), we detected a higher 
amount of secreted IL-10 was detected in the cultures where TLR9-deficient B cells were present 
(Fig.4B).  To determine if the suppressed T cell response was indeed due to B cells from 
TLR9fl/fl/CD19-Cre+ mice rather than cell contact between B cells and T cells, we repeated the 
experiment using a trans-well system (Research Design and Methods).  We first purified splenic 
B cells from TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice and stimulated with anti-
CD40 overnight.  After washing, we placed the pre-activated B cells in the trans-well inserts, 
with the splenic T cells and B cell-depleted APCs from wild-type NOD mice seeded in the lower 
wells, in the presence of anti-CD3 and anti-CD28.  In this culture system, there was direct cell-
cell contact between T cells and APCs from wild-type NOD mice, while B cells from 
TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice were separated from T cells by the 
trans-well insert.  We assessed T cell proliferation by 3H-thymidine incorporation and the content 
of secreted IL-10 in the supernatant.  In line with the co-culture results, we found impaired T cell 
proliferation, when the pre-activated B cells in the trans-well inserts were from TLR9fl/fl/CD19-
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Cre+ NOD mice (Fig.4C).  Again, T cell hypo-response was accompanied by higher IL-10 
secretion by B cells from TLR9fl/fl/CD19-Cre+ NOD mice (Fig.4D).  To further confirm the role 
of IL-10 in suppressing the T cell response, we blocked IL-10 signaling using mAb to the IL-10 
receptor in the trans-well system.  As expected, blocking IL-10 signaling significantly enhanced 
T cell proliferation, whereas T cell responses were impaired in the presence of control IgG 
(Fig.4E).  It is noteworthy that blockade of the IL-10 receptor also enhanced T cell proliferation 
when pre-activated B cells from TLR9fl/fl/CD19-Cre- NOD mice were present, compared to 
control IgG (Fig.4E).  To determine if the levels of IL10 in the systemic circulation were also 
altered by the absence of B cell-specific TLR9, we measured IL-10 in the serum samples of 
TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice.  Interestingly, we found a significant 
increase in circulating IL-10 in TLR9fl/fl/CD19-Cre+ NOD mice compared to TLR9fl/fl/CD19-
Cre- NOD mice regardless of age (Fig. 4F, 6-8 wks; Fig. 4G, 30-32wks).  Taken together, our 
results demonstrate that B cell TLR9 deficiency converted B cells to IL-10-producing Bregs that 
suppressed T cell responses.   
TLR9 deficiency in B cells confers protection against T1D development. 
To determine if TLR9-deficient B cells induce suppression of islet β-cell autoimmunity, we first 
assessed whether B cell-specific TLR9 deficiency dampened autoreactive T cells, especially 
cytotoxic CD8+ T cells by staining for IGRP-tetramer-specific CD8+ T cells.  Our results showed 
that the absence of B cell-specific TLR9 did not have noticeable effect on CD8 T cells including 
IGRP-tetramer-specific CD8+ T cells (Fig. S8, A-C).  Next, we assessed if B cell-specific TLR9 
deficiency affected the proportion and the function of Treg cells.  Interestingly, we found that the 
absence of B cell-specific TLR9 significantly increased the proportion of Treg cells (Fig.S9).  To 
test if the increased Tregs contribute to diabetes protection, we adoptively transferred 
splenoctyes from TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice to Rag-/- NOD 
recipients, after depleting Tregs cells.  In the absence of Tregs, diabetes development in the Rag-
/- NOD recipients that received splenoctyes from TLR9fl/fl/CD19-Cre+ mice was significantly 
delayed and reduced compared to the Rag-/- NOD recipients that received splenoctyes from 
TLR9fl/fl/CD19-Cre- mice (Fig.5A).  These results suggest that diabetes suppression in 
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TLR9fl/fl/CD19-Cre+ NOD mice is not due to Tregs, despite their increase.  To determine if 
TLR9-deficient B cells confer the diabetes suppression, we carried out a further set of adoptive 
transfers, in which we adoptively transferred purified splenic T cells from diabetic 
TLR9fl/fl/CD19-Cre- NOD mice (wild type), together with purified splenic B cells from non-
diabetic TLR9fl/fl/CD19-Cre+ or TLR9fl/fl/CD19-Cre- NOD mice, into Rag-/- NOD recipients.  
Diabetes development was significantly reduced in the Rag-/- NOD recipients that received B 
cells from TLR9fl/fl/CD19-Cre+ mice, compared to the Rag-/- NOD recipients that received B 
cells from TLR9fl/fl/CD19-Cre- NOD mice (Fig.5B).  To investigate if IL-10 played a role in 
diabetes suppression, we isolated splenic B cells from the Rag-/- NOD recipients and assessed 
IL-10 gene expression, with or without anti-CD40 stimulation, by qPCR.  In line with the results 
shown above, we found significantly higher IL-10 gene expression in the B cells from the Rag-/- 
NOD recipients that received B cells from TLR9fl/fl/CD19-Cre+ mice, compared to the Rag-/- 
NOD recipients that received B cells from TLR9fl/fl/CD19-Cre- NOD mice (Fig.5C).  This was 
found both with and without anti-CD40 stimulation, with significantly higher IL10 gene 
expression in TLR9-deficient B cells compared to TLR9-sufficient B cells. Our data suggest that 
B cells from TLR9fl/fl/CD19-Cre+ NOD mice exert stronger immunosuppressive function, 
mediated by the higher levels of the anti-inflammatory cytokine IL-10.
TLR9 regulates the cross talk between tissue inhibitor of metalloproteinase 1 (TIMP-1) and 
IL-10 in B cells 
To determine the molecular mechanism by which IL-10 is enhanced in B10reg cells in the 
absence of TLR9, we performed microarray analysis using purified splenic B cells, directly ex 
vivo, from TLR9fl/fl/CD19-Cre+ and TLR9fl/fl/CD19-Cre- NOD mice.  Among 3 down-regulated 
genes, we found that the gene expression of matrix metalloproteinase 19 (MMP-19) was 
strikingly lower in the spleen cells from TLR9fl/fl/CD19-Cre+ mice (Fig.5D, Table.1), which was 
confirmed by qPCR (Fig.5E).  Using Ingenuity Pathways Analysis (IPA, Qiagen), we identified 
that TLR9 and IL-10 interacted with MMP19 and that tissue inhibitors of metalloproteinases 
(TIMPs) could modulate these interactions (Fig.5F).  In addition to their role in extracellular 
matrix remodeling, TIMPs also have cytokine functions affecting cell differentiation, apoptosis 
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and cell growth [35, 36].  As TIMPs inhibit the activities of the matrix metalloproteinases 
(MMPs) [37], [38], down regulation of MMPs may suggest up-regulation of TIMPs.  To 
determine if TIMP-1 is up-regulated in TLR9-deficient B cells, with or without stimulation, we 
assessed the expression level of TIMP-1 by qPCR.  Indeed, TIMP-1 was highly up-regulated in 
the activated B cells from TLR9fl/fl/CD19-Cre+ mice, compared to their counterparts from 
TLR9fl/fl/CD19-Cre- NOD mice (Fig.5G).  The significant up-regulation of TIMP-1 was also 
seen in non-activated TLR9-deficient B cells although the scale was lower compared to the 
activated B cells (Fig.5G). 
To further establish the cross talk of TLR9 with TIMP-1/MMP-19 and IL-10, we stimulated 
splenic B cells from wild-type NOD mice with CpG and assessed the gene expression level of 
TIMP-1, MMP19 and IL-10 by qPCR.  Unstimulated B cells were used as controls.  Supporting 
the results shown earlier, CpG stimulation resulted in lower gene expression of TIMP-1 and IL-
10 (Fig.6A-B) but higher expression of MMP-19 (Fig.6C) compared to the controls.  
Interestingly, the expression level of CD40 paralleled IL-10 (Fig.6D), supporting our earlier 
results (Fig.1H).  Our results suggest novel cross-talk between TLR9 and TIMP-1/MMP-19, 
which regulates IL-10 in B cells. 
Discussion
As TLR9 is pivotal in the development of T1D [26], and is primarily expressed in B cells and 
plasmacytoid dendritic cells (pDCs) [39, 40], we aimed to clarify the role of TLR9 in B cells in 
development of spontaneous T1D.  Our key finding was that B cell TLR9 plays a critical role in 
immune tolerance to islet beta cell autoimmunity, as TLR9 deficiency in B cells strongly 
protected NOD mice from T1D development.  TLR9 modulated T1D susceptibility through 
different pathways, which included effects on B cell subsets, including MZ B cells, transitional B 
cells and B10-reg subsets.  In the absence of TLR9 in B cells, these B cell subsets, particularly 
B10-reg cells were enhanced, both in frequency and function.  At the molecular level, we 
discovered a novel regulatory network between TLR9 with TIMP1, MMP19, CD40 and the IL-
10 signaling pathway.  Our study confirmed an important function of B cells in influencing 
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immune tolerance whereby increased immune tolerance was observed in the absence of B cell 
TLR9.   
IL-10-producing Breg (B10) cells are important in health and disease, in humans and in mouse 
models [41-44], and B10 cells are considered to be an indispensable contributor to the 
maintenance of tolerance and immune homeostasis.  Previous studies suggested that CpG, a 
TLR9 agonist, induces B10 cells [45].  Interestingly, we found that the proportions    
CD1dhighCD5high B cells and IL-10-producing CD1dhighCD5high B cells in NOD mice are 
enhanced when B cells are deficient in TLR9.  Moreover, the increase of Bregs found in our 
study was age independent.  B cell-specific deficiency in TLR9 also altered the proportions of 
marginal zone and transitional B cells, namely increased marginal zone B cells and decreased 
transitional B cells.  Whilst we have confirmed that TLR9 signaling plays an important role in 
formation of different effector B cell subsets [46, 47], the role of TLR9 in B cells goes beyond 
this.  Our study demonstrated that B cell-specific deficiency of TLR9 led to an immune tolerant 
state, supported by B cell hypo-responsiveness to both innate and adaptive stimuli, as well as an 
impaired ability to promote optimal T cell responses.  Moreover, B cells with B cell-specific 
TLR9 deletion were able to suppress both spontaneous and induced T1D development.  All of 
these findings were associated with IL-10 production of B cells, regulated by TLR9.   
Interestingly, molecular analysis of TLR9-deficient and -sufficient B cells revealed only a 
limited number of gene expression differences and the expression of matrix metallopeptidase 19, 
Mmp19, was lowest in TLR9-deficient B cells, compared to TLR9-sufficient B cells.  The matrix 
metalloproteinase gene family includes over 20 genes that regulate the breakdown of 
extracellular matrix in normal physiological and disease processes [48, 49].  The expression of 
MMP and its inhibitor TIMP, tissue inhibitor of metalloproteinase, are essential in tissue 
remodeling and cell signaling [38, 50].  An earlier study showed that Mmp-19 is expressed in 
synovial blood vessels and in circulating T cells of patients with rheumatoid arthritis [51]. 
Other studies have reported that the MMP inhibitors, TIMPs, may play a role in the pathological 
processes in multiple sclerosis in humans [52, 53] and experimental autoimmune 
encephalomyelitis in animal models [54, 55].  Furthermore, Guedez and colleagues [35] have 
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reported that TIMP-1 regulates IL-10 in B cell differentiation in lymphoma cell lines.  However, 
little is known about the role of MMPs in the function of TLR9 and B cell regulation.  Using 
Ingenuity Pathway Analysis, we identified the network of TLR9-IL-10 with MMP and the MMP 
inhibitor TIMP-1 in B cells.  TLR9-deficient B cells have a marked reduction of MMP19 but 
highly increased TIMP1, with or without activation.  It is interesting that the expression of CD40 
in TLR9-deficient B cells was positively associated with the expression of IL-10 and TIMP1 
expression, but negatively associated with the expression of MMP-19.  Sanchooli and colleagues 
[56] reported an elevation of soluble CD154 (CD40 ligand) and TIMP1 in patients with multiple 
sclerosis.  Our study suggests a novel cross-talk loop of TLR9, MMPs/TIMP-1, IL-10 and CD40.  
Our results also demonstrate that TLR9 plays a vital role in this network, which leads to immune 
tolerance to islet β-cell autoimmunity.  Thus, TLR9 in B cells acts as a crucial modulator of T1D 
susceptibility.  
B cell depletion immunotherapy has been used for treating different autoimmune disorders with 
some success [57, 58].  However, B cell depletion also eliminates IL-10 producing Breg cells, 
which are important in immune tolerance to autoimmunity.  Our study provides pre-clinical 
information for selective molecular therapy by targeting TLR9 in B cells.  
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TLR9-deficient B cell 
ge e expressionFold Change P.value
Gm20257 NR_045007 7.07757 5.510315 0.33745 6.40E-07
Mmp19 NM_001164197 8.27076 4.308635 0.064163 1.38E-06
Tlr9 NM_031178 9.067313 5.851875 0.107661 1.68E-06
Pde3b NM_011055 7.112163 8.42422 2.482953 2.63E-06
Snora30 NR_034045 6.635437 8.76151 4.365277 3.91E-06
 
Page 22 of 44Diabetes
23
Figure legends 
Figure 1 –B cell-specific TLR9 deficiency protected against T1D by altering the frequency 
and function of B subsets.
A. TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ NOD littermates were observed for 
spontaneous diabetes, from 10 weeks of age. Diabetes development was assessed by testing 
weekly for glycosuria, and confirmed by measuring blood glucose (250mg/dl (13.9mmol/L)). B. 
Representative flow cytometric plots gated on single, live cells expressing B220+TCRbeta- and 
then gated as a quadrant on CD1d vs CD5 and IL-10. C-E demonstrate 6-8-week-old female 
mice (n=7/per group); C shows a graphical summary of flow cytometric analysis of B cells 
expressing CD1d+CD5+, while D and E, shows graphical summaries of the frequency of B cells 
expressing IL-10+ and IL-10+CD40+. F-H demonstrate 30-32week old non-diabetic female mice 
(n=4/per group); F shows a graphical summary of flow cytometric analysis of B cells expressing 
CD1d+CD5+, while G and H, show graphical summaries of B cells expressing IL-10+and IL-
10+CD40+.  Data were pooled from 2 independent experiments and assessed for significance 
using a Student’s T Test or 2-way ANOVA (C-H). A was assessed for significance using a log-
rank (Mantel-Cox) test. 
Figure 2 –B cells without TLR9 are hypo-responsive to both innate and adaptive immune 
stimuli in 6-8-week-old mice. 
Cell proliferation was assessed by 3H-thymidine incorporation, added at 48 hours, and was 
incubated with the cells for 18 hours prior to harvest. Data are presented as counts per minute 
(CPM) with the background subtracted (cells without stimulation).  A-D. Total splenocytes from 
both TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ NOD mice were stimulated in the 
presence of various concentrations of anti-CD40, Pam3csk4, LPS and CpG (n=3/per group). E-I. 
Splenic B cells from 6-8-week-old female TLR9fl/fl CD19-Cre- NOD mice and TLR9fl/fl CD19-
Cre+ NOD mice were isolated and stimulated in the presence of various concentrations of anti-
CD40 and IgM/anti-CD40, Pam3Csk4, LPS and CpG (n=3-5/per group). J, shows IL-10 in 
supernatants removed from the anti-CD40 cultures in E at 48 hours (n=5/per group). Data shown 
Page 23 of 44 Diabetes
24
were pooled from 2 independent experiments and assessed for significance using a Student’s T 
Test or 2-way ANOVA. 
Figure 3 –B cells without TLR9 are also hypo-responsive to both innate and adaptive 
immune stimuli in 30-32-week-old non-diabetic mice. 
A-E, Splenic B cells from both TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ NOD 
mice were isolated and stimulated in the presence of various concentrations of anti-CD40 and 
IgM/anti-CD40, Pam3Csk4, LPS and CpG in 30-32- week-old non-diabetic female mice 
(n=3/per group). F, supernatants removed from the anti-CD40 cultures in A at 48 hours were 
tested for IL-10 by ELISA (n=3-6/per group). Proliferation was assessed by 3H-thymidine 
incorporation, added at 48 hours and incubated with cells for 18 hours. Data are presented as 
counts per minute (CPM), with the background subtracted (cells without stimulation). Data 
shown were pooled from 2 independent experiments and assessed for significance using a 
Student’s T Test or 2-way ANOVA.
Figure 4 –TLR9 regulates the fate of IL-10-producing B cells.
A, proliferation of T cells; total splenic B cells from both TLR9fl/flCD19-Cre- NOD and 
TLR9fl/flCD19-Cre+ NOD mouse spleens (stimulated by anti-CD40, 6-8-week-old female mice) 
co-cultured with T cells from 6-8-week-old female wild-type NOD mice with anti-CD3 and anti-
CD28 in co-culture with background counts subtracted (from cultures without B cells) (n=3-
4/per group). B, supernatants removed from the culture in A at 48 hours were tested for IL-10 by 
ELISA (n=4/per group). C shows proliferation of T cells; total splenic B cells from both 6-8-
week-old TLR9fl/flCD19-Cre- NOD and TLR9fl/flCD19-Cre+ NOD mice were stimulated by anti-
CD40 in inserts with T cells from 6-8-week-old female wild-type NOD mice in the bottom 
chamber with anti-CD3 and anti-CD28, in a transwell system (n=7-8/per group). D, supernatants 
removed from the cultures in C at 48 hours were tested for IL-10 by ELISA (n=6/per group). E 
shows proliferation of T cells with either the IL-10 receptor blocking mAb or control IgG added 
into co-culture transwell system (n=6/per group). Proliferation was assessed by 3H-thymidine 
incorporation, added at 48 hours and incubated with the T cells for 18 hours. F, serum from both 
6-8-week-old female TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ NOD mice were 
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tested for IL-10 by ELISA (n=11-12/per group). G, serum from both 30-32-week-old female 
TLR9fl/flCD19-Cre- NOD and TLR9fl/flCD19-Cre+ NOD mice were tested for IL-10 by ELISA 
(n=6-9/per group). Data shown were pooled from 2 independent experiments and assessed for 
significance using a Student’s T Test or 2-way ANOVA. The final concentration of anti-CD3 
was 1:400, with 1μg /ml anti-CD28.
Figure 5 –TLR9 deficiency in B cells confers protection against T1D development.
A, Spontaneous diabetes in Rag-/- NOD mice (females, 4-5 weeks old) following adoptive 
transfer of Treg–depleted splenocytes (8x107/mouse) from TLR9fl/flCD19-Cre- NOD and 
TLR9fl/flCD19-Cre+ NOD mice (females. 6-8 weeks old).  Diabetes was assessed by weekly 
glycosuria testing and confirmed after blood glucose testing (250mg/dl (13.9mmol/L)) (n=6/per 
group).  B, Spontaneous diabetes in Rag-/- NOD mice (females, 4-5 weeks old) following 
adoptive transfer of purified T cells (5x106/mouse) from diabetic TLR9fl/flCD19-Cre- NOD mice 
together with purified splenic B cells (5x106/mouse) from non-diabetic TLR9fl/flCD19-Cre- NOD 
and TLR9fl/flCD19-Cre+ NOD mice (females, 6-8 weeks old). Diabetes was assessed by weekly 
glycosuria testing and confirmed after blood glucose testing (250mg/dl (13.9mmol/L)) (n=9-
13/per group). C, the levels of IL-10 mRNA in splenic B cells from TLR9fl/flCD19-Cre- NOD 
mice and TLR9fl/flCD19-Cre+ NOD mice with (left) and without (right) anti-CD40 stimulation 
(n=3-6/per group). D, microarray heat map showing averaged and normalized gene expression 
from purified splenic B cells from TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ NOD 
mice (6-8-week-old female mice) (n=3/per group). Averaged gene expression values are plotted 
based on the data ranges, where the lower expression is represented in blue, while higher gene 
expression is represented in red. E, the microarray levels of MMP19 in isolated splenic B cells 
without anti-CD40 stimulation from TLR9fl/flCD19-Cre- NOD mice and TLR9fl/flCD19-Cre+ 
NOD mice (6-8-week-old, female mice) (n=3/per group). F, gene network identified using IPA 
analysis. Dashed lines indicate indirect interactions, while solid lines indicate direct interactions. 
Arrow indicates direction of signaling pathway. G, the levels of TIMP-1 mRNA in isolated 
splenic B cells with (left) and without (right) anti-CD40 stimulation from TLR9fl/flCD19-Cre- 
NOD mice and TLR9fl/flCD19-Cre+ NOD mice (6-8-week-old, female mice) (n=3-6/per group). 
A-B, Log-rank (Mantel-cox) test was used for statistical analysis. Data were pooled from 2 
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independent experiments. Data shown in C, E and G were pooled from 2-3 independent 
experiments and assessed for significance using a Student’s T Test. 
Figure 6 –TLR9 regulates the cross talk between tissue inhibitor of metalloproteinase 1 
(TIMP1) and IL-10 signaling pathways in B cells.
A-D, the levels of TIMP1, IL-10, MMP19 and CD40 mRNA from CpG-stimulated (10ng/ml) 
isolated splenic B cells from 6-8-week-old, female TLR9fl/flCD19-Cre- NOD and TLR9fl/flCD19-
Cre+ NOD mice (n=3-6/per group). Data shown were pooled from 2-3 independent experiments 
and assessed for significance using a Student’s T Test.  
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Supplementary Figure Legends
Figure S1 – B cell-specific TLR9 deficiency protected NOD mice from developing insulitis. 
Pancreata from 20-wk-old female TLR9fl/fl/CD19-Cre- and TLR9fl/fl/CD19-Cre-+ NOD mice 
(n=6-7 mice/group, 105-116 islet/group) were assessed for immune cell infiltration.  The insulitis 
was scored by the percentage of infiltration in each observed islet.  Chi-square test was used for 
statistical analysis.  
Figure S2 – Representative gating strategy of flow cytometry.  A: Immune cells from 
splenocytes were first gated according to the SSA and FSC. The gated immune cells were further 
gated on the live cells using Zombie Dye (BioLegend). Gated live cells (Zombie Dye negative) 
were then gated using isotype control antibody (rat IgG2b) plot. Isotype control antibody negative 
but B200+ cells were selected for further B cell subset analysis. B: Representative flow cytometry 
plots of gating CD21 and CD23 after gating on B cells (B220+). 
Figure S3- The absolute cell number of different B cell subsets in different lymphoid tissues.
Immune cells were isolated from different lymphoid tissues of TLR9fl/fl/CD19-Cre- and 
TLR9fl/fl/CD19-Cre-+ NOD mice (females, 6-8 weeks). Absolute cell numbers of different B cell 
subsets were calculated as percentage of each subset in flow cytometric analysis (105) multiplied 
by the total cell numbers harvested from each tissue. Graphical summaries of the different B cell 
subsets are shown (A-E). Data were pooled from 2 independent experiments and assessed for 
significance using an unpaired, two-tailed Student’s t Test.  
Figure S4 – B cell-specific TLR9 deficiency altered the frequency of B cell subsets in different 
lymphoid tissues at different age
A and B show graphical summaries of B cells expressing CD21highCD23low and CD21highCD23high 
in 6-8-week-old female mice (n=7/group). C and D show graphical summaries of B cells 
expressing CD21highCD23low and CD21highCD23high in 30-32-week-old non-diabetic female mice 
(n=4/group). Data were pooled from 2 independent experiments and assessed for significance 
using a Student’s t test.
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Figure S5- The differences in IgM+ and IgD+ single and double positive B cell subsets in 
different lymphoid tissues.
A-B demonstrate flow cytometric profiles from 6-8-week-old female mice (n=6/group); A shows a 
graphical summary of flow cytometric analysis of B cells expressing IgM+IgD-, while B, shows 
graphical summaries of the frequency of B cells expressing IgM+IgD+. Data were pooled from 2 
independent experiments and assessed for significance using a Student’s t test.
Figure S6- B cell-specific TLR9 deficiency decreased circulating IgG1. 
Circulating immunoglobulins (IgM, IgA, IgG and IgG1) were assessed from the serum samples of 
10-12-week-old female mice (n=4-8/group) by ELISA.  The concentration of each isotype was 
calculated based on the standard curve, respectively. Two-tailed unpaired Student’s t test was used 
for the statistical analysis.    
Figure S7- B cell-specific TLR9 deficiency decreased Blimp1- plasmacytes. Immune cells from 
different lymphoid tissues were isolated from 6-8-week-old female mice (n=5/group) followed by 
staining with markers for B cells and plasmacytes and analysis by flow cytometry. A, proportion of 
B220+CD138-Blimp1+ plasmacytes; B, B220+CD138+Blimp1+ plasmacytes; C, 
B220+CD138+Blimp1- plasmacytes.  Two-tailed unpaired Student’s t test was used for the 
statistical analysis. 
Figure S8- B cell-specific TLR9 deficiency did not affect CD8 T cells.  Immune cells from 
different lymphoid tissues were isolated from 6-8-week-old female mice (n=5/group) followed by 
staining with the markers for different CD8+ T cells and analysis by flow cytometry.  A, 
proportion of naïve CD8+ T cells (TCRβ+CD8+CD44-CD62L+); B, proportion of memory CD8+ 
T cells (TCRβ+CD8+CD44+CD62L-); C, proportion of IGRP-tetramer+ CD8 T cells 
(TCRVβ8+CD8+IGRP tetramer+).  Two-tailed unpaired Student’s t test was used for the 
statistical analysis. 
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Figure S89- B cell-specific TLR9 deficiency increased Treg cells.  Immune cells from different 
lymphoid tissues were isolated from 6-8-week-old female mice (n=4-5/group) followed by staining 
with the Treg markers (TCRβ, CD4, CD25 and Foxp3).  Two-tailed unpaired Student’s t test was 
used for the statistical analysis. 
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